Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

FDA Unveils Guidance for Biosimilar Development

Feb 10, 2012

After months of anticipation, FDA finally issued guidances last month that outlines its recommendations for developing and approving biosimilar therapies.

Costs and Benefits of Health Reform

Feb 1, 2012

Will expanded markets and ACOs offset higher rebates, added fees, and closer scrutiny of marketing and prices?

New Year, New Issues

Jan 1, 2012

Look for action in 2012 on drug access, shortages, innovation, and transparency.

FDA Gets a New Look

Dec 1, 2011

Agency expansion and globalization promote innovation, collaboration, and organizational changes

The Drug Shortages Struggle

Nov 1, 2011

Clamor for critical therapies prompts probes of prices, production practices.

Sidney Wolfe: Pharma's Unlikely Best Friend

Oct 1, 2011

Sidney Wolfe, MD, Director, Public Citizen's Health Research Group

Francis Collins: Guiding a Revolution in Science

Oct 1, 2011

Francis Collins, MD, PhD, Director, National Institutes of Health

Henry Waxman: "Representing" Healthcare to the Fullest

Oct 1, 2011

Henry Waxman, Congressional Representative from Los Angeles, California

Janet Woodcock: At the Helm of Industry

Oct 1, 2011

Janet Woodcock, MD, Director, FDA Center for Drug Evaluation and Research

ADVERTISEMENT

Click here